BioNxt Accelerates R&D with Move to Gen-Plus Laboratory in Munich, Germany, Expanding Drug Delivery Research Capabilities
VANCOUVER, BC / ACCESS Newswire / January 21, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, is excited to announce a major milestone in its research and development journey. The company is transitioning its cutting-edge R&D activities to the Gen-Plus Contract Research and Development Organization (CRDO) in Munich, Germany, with operations scheduled to begin on March 1, 2025. This move underscores BioNxt's commitment to scientific innovation and advancing solutions for unmet medical needs.
The new laboratory facility provides BioNxt with access to cutting-edge technologies, an expanded 1,000-square-meter research environment, and strategic opportunities for scientific collaboration within Europe's biotech hub. The transition is expected to accelerate the company's ongoing projects, particularly in the areas of drug delivery systems, neurodegenerative disease therapeutics, and next-generation biomedical technologies.
BioNxt Relocates to Gen-Plus: Strategic Importance for Advanced R&D
By leveraging the advanced and innovative infrastructure of the Gen-Plus Laboratory, BioNxt aims to harness the facility's 1,000 square meters of state-of-the-art space designed for high-potency active pharmaceutical ingredients and GMP-compliant processes. The lab's specialized equipment, including advanced technologies for solid and semi-solid dosage forms and capabilities in drug printing, will empower BioNxt to:
Enhance R&D Capabilities: With access to cutting-edge equipment and analytical tools, BioNxt is better positioned to develop innovative solutions and optimize its research outcomes.
Foster Collaborations: The Munich location enables proximity to leading research institutions, biotech firms, and academic experts, paving the way for impactful partnerships.
Accelerate Innovation: The advanced resources at Gen-Plus Laboratory allow BioNxt to streamline workflows and reduce the time to bring groundbreaking therapies to market.
"BioNxt's transition to Gen-Plus marks a pivotal moment for BioNxt," said Hugh Rogers, CEO of BioNxt Solutions Inc. "This transition is both strategic and timely, and unlocking new possibilities for added strength on IP with innovation and reinforcing our mission to deliver transformative therapies for patients worldwide. We are thrilled about the opportunities that this new chapter brings, providing Impact on Current and Future projects."
BioNxt's innovative projects, including the development of advanced drug delivery systems such as sublingual thin films, transdermal patches, and other targeted therapeutic platforms, stand to gain significant advantages from the advanced capabilities at the Gen-Plus Laboratory. This cutting-edge facility is poised to accelerate preclinical research timelines, enhance formulation accuracy, and streamline the development of next-generation therapeutics.
About Gen-Plus GmbH & Co. KG
Gen-Plus GmbH & Co. KG, headquartered in Munich, Germany, is a premier Contract Research and Development Organization (CRDO) with over 25 years of experience in pharmaceutical formulation and development. The company operates a 1,000-square-meter state-of-the-art laboratory equipped for handling high-potency active pharmaceutical ingredients and licensed for GMP-compliant production, including narcotics.
Gen-Plus specializes in developing solid and semi-solid dosage forms, transdermal patches, and oral thin films, offering end-to-end services from feasibility studies to clinical trial supply production. The company leverages advanced technologies such as hot-melt extrusion, drug printing, and amorphization of APIs to deliver comprehensive pharmaceutical solutions.
Committed to innovation, Gen-Plus collaborates with leading European research institutions and biotech companies to drive advancements in pharmaceutical solutions. The company's expertise and cutting-edge infrastructure make it a trusted partner in accelerating drug development and commercialization.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 778.598.2698
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains "forward-looking information" within the meaning of applicable securities laws. Forward-looking information is based on management's expectations, estimates, projections, and assumptions as of the date of this press release. It is subject to significant risks, uncertainties, and other factors that could cause actual results or events to differ materially from those expressed or implied. These risks and uncertainties include, but are not limited to, general economic conditions, market conditions, regulatory risks, technological advancements, and other factors described in the Company's public disclosure filings.
Readers are cautioned not to place undue reliance on forward-looking information, as actual outcomes may differ significantly from those expressed or implied, due to various factors beyond the Company's control. The Company undertakes no obligation to update or revise any forward-looking information, except as required by law.
SOURCE: BioNxt Solutions Inc.
View the original press release on ACCESS Newswire
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Latest GA Autonomous Jet Demo Features Live Air-to-Air Engagement Capability17.7.2025 18:10:00 CEST | Press release
Autonomous Tasking With TacACE and Optix.C2 Showcase Maturity and Operational Readiness SAN DIEGO, CALIFORNIA / ACCESS Newswire / July 17, 2025 / General Atomics Aeronautical Systems, Inc. (GA-ASI) and General Atomics Integrated Intelligence, Inc. (GA-Intelligence) successfully completed a groundbreaking demonstration on July 8, integrating technologies across multiple affiliates to showcase long-range kill chain effects, including an autonomous air-to-air engagement. The flight integrated local and global sensor fusion to deliver real-time situational awareness and autonomous tasking to an airborne MQ-20 Avenger® through the Tactical Autonomy Core Ecosystem (TacACE) to close the kill chain and showcase the system's maturity and operational readiness for the warfighter. The event featured the integration of a Collaborative Combat Aircraft (CCA), a fully compliant government-owned autonomy implementation, and beyond-line-of-sight (BLOS) Command and Control (C2). The MQ-20 unmanned jet,
Belgian Aircrew Completes MQ-9B Training17.7.2025 18:05:00 CEST | Press release
GA-ASI's MQ-9B SkyGuardian® Training Was Conducted at Multiple Sites, Including Flight Test & Training Center and Desert Horizon SAN DIEGO, CALIFORNIA / ACCESS Newswire / July 17, 2025 / The first Belgian aircrew has completed training to operate the world's leading remotely piloted aircraft (RPA): the MQ-9B SkyGuardian®. General Atomics Aeronautical Systems, Inc. (GA-ASI), designer and developer of the MQ-9B, provided the extensive aircrew training that culminated at GA-ASI's Desert Horizon test facility in El Mirage, California, following stops in Belgium and GA-ASI's Flight Test & Training Center in North Dakota. "Providing all-encompassing training for the aircrews of our customers goes hand in hand with delivering the world's most capable RPA," said GA-ASI President David R. Alexander. "Completing this training ensures that Belgium is ready and able to operate their MQ-9Bs and maximize the benefits that come from long-range, high-endurance RPA." The scope of the training is focuse
A New Transatlantic Partnership for European CCA17.7.2025 18:00:00 CEST | Press release
General Atomics announces plans for rapid international uncrewed fighter development FAIRFORD, UK / ACCESS Newswire / July 17, 2025 / General Atomics is taking a bold step toward rapidly delivering a European Collaborative Combat Aircraft (CCA) - based on a mature U.S. platform, assembled in Europe, with European mission systems - by aligning its independent U.S. and German aerospace affiliates under a teamed operation.YFQ-42A The new aircraft is derived from the U.S. Air Force's YFQ-42A prototype, currently in ground testing and scheduled for first flight later this summer, designed and built by General Atomics Aeronautical Systems, Inc. (GA-ASI) in San Diego, Calif. European mission system customization and manufacturing in Europe will be supported by General Atomics' German aerospace affiliate, General Atomics Aerotec Systems GmbH (GA-ATS), headquartered in Oberpfaffenhofen, near Munich. Leveraging the prior investments of these established aerospace companies on both sides of the A
The Digital Banker17.7.2025 15:30:00 CEST | Press release
In this July 2025 article for the Fast Company Executive Board, Avtar Sehmbi of the Forbes Technology Council explains why Chief Technology Officers (CTOs) are increasingly positioned to lead the future of banking. LONDON, GB / ACCESS Newswire / July 17, 2025 / Artificial intelligence (AI) and other emerging technologies are reshaping banking by automating tasks, enhancing data analysis, and enabling personalized services. These tools improve risk management, streamline operations, and boost profitability. Institutions like JPMorgan Chase and Bank of America are already leveraging AI for fraud detection, customer service, and advanced analytics. Meanwhile, AI-powered hedge funds and neobanks use technology to deliver tailored experiences and outperform their peers.Avtar Sehmbi The Digital Banker Fast Company Avtar Sehmbi the Digital banker This shift isn't theoretical; it's already well underway. Digital systems are fully embedded into the everyday operations of financial institutions,
Global Sports Brand U.S. Polo Assn. Launches First Retail Store in Berlin, Germany16.7.2025 16:37:00 CEST | Press release
Brand Targets Aggressive Retail, Wholesale and Ecommerce Expansion WEST PALM BEACH, FL AND BERLIN, GERMANY / ACCESS Newswire / July 16, 2025 / U.S. Polo Assn., the official brand of the United States Polo Association (USPA), is proud to announce its first retail store in Germany alongside its brand partners Incom S.p.a. and Modevertrieb Sarnacchiaro GmbH (MVS). The location of the first U.S. Polo Assn. store in the heart of Berlin is at the premier Alexa Mall at Alexanderplatz and marks the beginning of a strategic retail rollout across the country, which solidifies the multi-billion-dollar brand's global presence in Germany. The new Berlin store is offering a curated selection of men's, women's, undergarments, and beachwear collections - a perfect mix of sports heritage and contemporary spirit.U.S. Polo Assn. Executives J. Michael Prince, Antonio Sarnacchiaro, and Lorenzo Nencini with U.S. Polo Assn. Models U.S. Polo Assn. is a symbol of style that blends sports inspiration and authen
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom